Issuu

Tau-targeted strategies are gaining clinical traction.

A biennial tau landscape turns fragmented data into a field assessment.

Examples of Inputs GlobalData + SciFinder

Special thanks to the coauthors over the years, especially Martyn Pritchard (3DC), Isabel Gonzalez (3DC), Pat May (ADvantage Neuroscience), and Lymor Barnhard (RCF), who helped curate the data shown today.

Since 2023, there are 69 new programs in the tau pipeline. Most of the development is concentrated in early stages.

Included programs must target tau directly or indirectly through other types of neuropathology (e.g., inflammation, synaptic dysfunction, oxidative injury, and others)

*Data indexed through June 1, 2026

2026*

Clinical translation remains a bottleneck for tau programs. 79% of the 2026* entries are not yet clinical assets.

*Data indexed through June 1, 2026

Despite notable advancements in the field, several programs have

been terminated.

Semorinemab

• Ph. 2 TAURIEL and LAURIET; Roche/Genentech collaboration terminated, and rights returned to AC Immune.

Posdinemab

• Ph. 2: Autonomy; J&J review found posdinemab did not achieve statistical significance in slowing clinical decline.

Ceperognastat, ASN-51, BIIB113

• All oral O-GlcNAcase inhibitors withdrawn in Ph. 1 or 2 trials in 2024-2025

BMS-986446

• Anti-MTBR tau mAb initiated Ph. 2 in 2024

• C-terminal tau mAb (pS413) recruiting Ph. 2 since last summer

FNP-223

• O-GlcNAcase inhibitor, Ph. 2 fully recruited for PSP MK-2214

BIIB080

• Announced Ph. 2 results, plans to advance to registrational development

NIO752

• Tau reducing ASO announced Ph.3 in PSP (PRESERVE)

Small molecule and mAb/antibody approaches account for more than half of all active assets.

*Data indexed through June 1, 2026

Across the clinical programs, small molecule and mAb/antibody approaches are nearly equally represented.

From candidate definition to partner-ready handoff, T-PEP supports data packages suitable for clinical-stage development.

FUNDERS

Alzheimer’s Association +

Rainwater Charitable Foundation

Joint program with milestone monitoring.

DISEASE SCOPE

Tauopathies

AD, PSP, FTD and related tau disorders.

AWARD SHAPE

$750k / up to 2 yrs

Nonprofit indirects up to 10%; no for-profit indirects.

T-PEP “sweet spot”

DEVELOPMENT STAGE

Preclinical de-risking

Lead optimization, in vivo PoC and INDenabling studies.

The strongest T-PEP pitch is a de-risking plan: define the candidate, specify the TPP, run the decisive translational studies, and leave the project materially more partnerable. Mechanistic

T-PEP has generated significant follow-on leverage across 23 programs (2018-2024).